Prosaposin gene expression and the efficacy of a prosaposin-derived peptide in preventing structural and functional disorders of peripheral nerve in diabetic rats

Journal of Neuropathology and Experimental Neurology

Volumn 58, Issue 6, 1999, Pages 628-636

  Calcutt, Nigel A ^a   Campana, W Marie ^b   Eskeland, Nahida L ^b   Mohiuddin, Liza ^a   Dines, Kevin C ^a   Mizisin, Andrew P ^a   O'Brien, John S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetes; Neuropathy; Pain; Prosaposin; Substance P.

Indexed keywords

NEUROTROPHIC FACTOR; PROSAPOSIN; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DIABETES MELLITUS; DIABETIC NEUROPATHY; FEMALE; GENE EXPRESSION; NERVE CONDUCTION; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT;

EID: 0033030069     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199906000-00007     Document Type: Article

References (53)

1. Ward JD, Barnes CG, Fisher DJ, Jessop JD, Baker RWR. Improvement in nerve conduction following treatment in newly diagnosed diabetics. Lancet 1971;1:428-31
2. Gregersen G. A study of the peripheral nerves in diabetic subjects during ischaemia. J Neurol Neurosurg Psych 1968;31:175-81
3. Benbow SJ, Chan AW, Bowsher A, McFarlane IA, Williams G. A prospective study of painful symptoms, small fibre function and periphreal vascular disease in chronic painful diabetic neuropathy. Diabetic Med 1994;11:17-21
4. Thomas PK, Lascelles RG. The pathology of diabetic neuropathy. Q J Med 1966;35:489-509
5. Greene DA, DeJesus PV, Winegrad AI. Effects of insulin and dietary myo-inositol on impaired peripheral nerve MNCV in streptozotocin diabetes. J Clin Invest 1975;55:1326-36
6. Seneviratne KN, Peiris OA. The effect of ischaemia on the excitability of sensory nerves in diabetes mellitus. J Neurol Neurosurg Psych 1968;31:348-53
7. Calcutt NA, Malmberg AB, Yamamoto T, Yaksh TL. Tolrestat treatment prevents modification of the formalin test model of pain in hyperglycemic rats. Pain 1994;58:413-20
8. Tomlinson DR, Stevens EJ, Diemel LT. Aldose reductase inhibitors and their potential for the treatment of diabetic complications. Trends in Pharmacol Sci 1994;15:293-7
9. Pfeifer MA, Schumer MP. Clinical trials of diabetic neuropathy: Past, present, and future. Diabetes 1995;44:1355-61
10. Fernyhough P, Diemel LT, Brewster WJ, Tomlinson DR. Deficits in sciatic nerve neuropeptide content coincide with a reduction in target tissue nerve growth factor messenger RNA in streptozotocin-diabetic rats: effects of insulin treatment. Neurosci 1994;62:337-44
11. Fernyhough P, Diemel LT, Brewster WJ, Tomlinson DR. Altered neurotrophin mRNA levels in peripheral nerve and skeletal muscle of experimentally diabetic rats. J Neurochem 1995;64:1231-7
12. Fernyhough P, Diemel LT, Hardy J, Brewster WJ, Mohiuddin L, Tomlinson DR. Human recombinant nerve growth factor replaces deficient neurotrophic support in the diabetic rat. Eur J Neurosci 1995;7:1107-10
13. Hell wig R, Hartung H D. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes: A possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 1990;28:258-67
14. Calcutt NA, Muir D, Powell HC, Mizisin AP. Reduced ciliary neuronotrophic factor-like activity in nerves from diabetic or galactosefed rats. Brain Res 1992;575:320-24
15. Rodriguez-Pena A, Botana M, Gonzalez M, Requejo E Expression of neurotrophins and their receptors in sciatic nerve of experimentally diabetic rats. Neurosci Lett 1995;200:37-40
16. Maeda K, Fernyhough P, Tomlinson DR. Regenerating sensory neurones of diabetic rats express reduced levels of mRNA for GAP-43, gamma-preprotachykinin and the nerve growth factor receptors, trkA and p75NGFR. Mol Brain Res 1996;37:166-74
17. Delcroix JD, Tomlinson DR, Fernyhough P. Diabetes and axotomy-induced deficits in retrograde axonal transport of nerve growth factor correlate with decreased levels of p75LNTR protein in lumbar dorsal root ganglia. Mol Brain Res 1997;51:82-90
18. Jakobsen J, Brimijoin S, Skau K, Sidenius P, Wells D. Retrograde axonal transport of transmitter enzymes, fucose labelled protein, and NGF in streptozotocin diabetic rats. Diabetes 1981;30:797-803
19. Diemel LT, Brewster WJ, Fernyhough P, Tomlinson DR. Expression of neuropeptides in experimental diabetes; effects of treatment with nerve growth factor or brain-derived neurotrophic factor. Mol Brain Res 1994;21:171-75
20. Mizisin AP, Bache M, DiStefano PS, Acheson A, Lindsay RM, Calcutt NA. BDNF attenuates functional and structural disorders in nerves of galactose-fed rats. J Neuropathol Exp Neurol 1997;56: 1290-301
21. O'Brien JS, Kishimoto Y. Saposin proteins: Structure, function, and role in human lysosomal storage disorders. FASEB J 1991;5:301-8
22. Hineno T, Sano A, Kondoh K, Ueno S, Kakimoto Y, Yoshida K, Secretion of sphingolipid hydrolase activator precursor, prosaposin. Biochem Biophys Res Commun 199;176:668-74
23. Harzer K, Paton BC, Poulos A, et al. Sphingolipid activator protein deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: Biochemical signs of combined sphingolipidoses. Eur J Ped 1989;149:31-9
24. Schnabel D, Schroder M, Furst W, et al. Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene. J Biol Chem 1992;267:3312-5
25. Fujita N, Suzuki K, Vanier MT, et al. Targeted disruption of the mouse sphingolipid activator protein gene: A complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Human Mol Gen 1996;5:711-25
26. O'Brien JS, Carson GS, Seo HC, Hiraiwa M, Kishimoto Y. Identification of prosaposin as a neurotrophic factor. Proc Natl Acad Sci 1994;91:9593-6
27. Campana WM, Hiraiwa M, Addison KC O'Brien JS. Induction of MAPK phosphorylation by prosaposin and prosaptide in PC12 cells. Biochem Biophys Res Commun 1996;229:706-12
28. Gillen C, Gleichmann M, Spreyer P, Müller HW. Differentially expressed genes after peripheral nerve injury. J Neurosci Res 1995;42:159-71
29. Kotani Y, Matsuda S, Sakanaka M, Kondoh K, Ueno S, Sano A. Prosaposin facilitates sciatic nerve regeneration in vivo. J Neurochem 1996;66:2019-25
30. O'Brien JS, Carson GS, Seo HC, et al. Identification of the neurotrophic factor sequence of prosaposin. FASEB J 1995;9:681-85
31. Calcutt NA, Mizisin AP, Kalichman MW. Aldose reductase inhibition, doppler flux and conduction in diabetic rat nerve. Eur J Pharmacol 1994;251:27-33
32. Calcutt NA, Tomlinson DR, Willars GB. Ganglioside treatment of diabetic rats: Effects on nerve adenosine triphosphatase activity and motor nerve conduction velocity. Life Sci 1988;42:1515-20
33. Hiraiwa M, Campana WM, Mizisin AP, Mohiuddin L, O'Brien JS. Prosaposin: A myelinotrophic protein that promotes expression of myelin constituents and is secreted after nerve injury. Glia 1999 (in press)
34. Conti AM, Malosio ML, Scarpini E, et al. Myelin protein transcripts increase in experimental diabetic neuropathy. Neurosci Lett 1993;161:203-6
35. Berti-Mattera L, Day N, Peterson RG, Eichberg J. An aldose reductase inhhibitor but not myo-inositol blocks enhances polyphosphoinositide turnover in peripheral nerve from diabetic rats. Metabolism 1996;45:320-7
36. Sharma AK, Thomas PK. Peripheral nerve structure and function in experimental diabetes. J Neurol Sci 1974;23:1-15
37. Hiraiwa M, Campana WM, Martin BR, O'Brien JS. Prosaposin receptor: Evidence for a G-protein-associated receptor. Biochem Biophys Res Commun 1997;240:415-18
38. Qi X, Qin W, Sun Y, Kondoh K, Grabowski G. Functional organization of saposin C. Definition of the neurotrophic and acid betaglucosidase activation regions. J Biol Chem 1996;271:6874-80
39. Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997;46 Suppl 2: S31-S37
40. Jakobsen J. Axonal dwindling in early experimental diabetes. I. A study of cross sectioned fibers. Diabetologia 1976;12:539-46
41. Greene DA. Metabolic abnormalities in diabetic peripheral nerve: relation to impaired function. Metabolism 1983;32:118-23
42. Misasi R, Sorice M, Carson GS, et al. Prosaposin and prosaptide, a peptide from prosaposin, induce an increase in ganglioside content on NS20Y neuroblastoma cells. Glycoconjugate J 1996;13: 195-202
43. Figliomeni B, Bacci B, Panozzo C, Fogarolo F, Triban C, Fiori MG. Experimental diabetic neuropathy. Effect of ganglioside treatment on axonal transport of cytoskeletal proteins. Diabetes 1992;41:866-71
44. Mohiuddin L, Fernyhough P, Tomlinson DR. Reduced levels of mRNA encoding endoskeletal and growth-associated proteins in sensory ganglia in experimental diabetes. Diabetes 1995;44:25-30
45. McLean WG. The role of axonal cytoskeleton in diabetic neuropathy. Neurochem. Res 1997;22:951-6
46. Robinson JP, Willars GB, Tomlinson DR, Keen P. Axonal transport and tissue contents of substance P in rats with long-term streptozotocin-diabetes. Effects of the aldose reductase inhibitor 'statil'. Brain Res 1987;426:339-48
47. McCarthy PW, Lawson SN. Cell type and conduction velocity of rat primary sensory neurons with substance P-like immunoreactivity. Neurosci 1989;28:745-53
48. Lindsay RM, Harmar AJ. Nerve growth factor regulates expression of neuropeptide genes in adult sensory neurons. Nature 1989;337: 362-4
49. Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA. Nerve growth factor administration protects against diabetic sensory neuropathy. Brain Res 1994;634:7-12
50. Lewin GR, Rueff A, Mendell LM. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur J Neurosci 1994;6:1903-12
51. Campana WM, Hiraiwa H, O'Brien JS. Prosaptide activates the MAPK pathway by a G-protein-dependent mechanism essential for enhanced sulfatide synthesis by Schwann cells. FASEB J. 1998;12: 307-14
52. Hiraiwa M, Taylor EM, Campana WM, Darin S, O'Brien JS. Cell death prevention, mitogan-activated protein kinase stimulation, and increased sulfatide concentrations in Schwann cells and oligodendrocytes by prosaposin and prosaptides. Proc Nat Acad Sci 1997;94:4778-81
53. Kirkpatrick LL, Brady S. Modulation of the axonal microtubule cytoskeleton by myelinating Schwann cells. J Neurosci 1994;14: 7440-50